2024 Annual Report: Preparing for a sustainable future
Building on success
Ecraid recently published its 2024 Annual Report. The report provides a comprehensive overview of our achievements from the last year. As the end of the primary funding period approaches (2026), Ecraid is preparing for a sustainable future. Therefore, this year we put a lot of effort into professionalising our organisation and initiating new collaborations while enhancing existing ones.
In the forward, CEO Marc Bonten emphasises that Ecraid has firmly established a position within the European infectious disease research field, Several new collaborations, such as PIPELINE, show Ecraid's growing relevance,
Balancing academic vision with financial stability
With a 39% increase in revenue and a positive result, Ecraid's Management Board is pleased with the financial outcome. Additionally, the share of revenue from commercial partners increases and was (for the first time) bigger than the revenue from non-commercial partners.
The balance between our academic aspirations and the financial resources needed to realise them is one of the themes of this annual report. Ecraid Coordinating Committee member, Peter Horby, addresses this point in an interview included in the report.
Investing in the future of clinical research
Executing high-impact studies is a key pillar for Ecraid, and the annual report offers an overview of the studies executed in 2024. Another focus in investing in the next generation of clinical researchers. We believe that providing the next generation with equal access to knowledge and a community where they can grow their expertise, network, and skills is essential.
That is underscored by the interview with early-career researcher Jacopo Garlasco, member of the EPI-Net team from Verona. His and other interviews, insights, financial figures, and more make this 2024 Annual Report a worthwhile read for everyone interested in Ecraid and the future of clinical research in infectious diseases.